Last updated on January 2020

Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy

Brief description of study

This is a study investigating the effect of MEDI7352 on chronic pain in patients with painful diabetic neuropathy.

The study incudes a screening period of up to 45 days and a 12-week treatment period during which MEDI7352 or placebo will be administered intravenously (IV) on 6 occasions, with each dose separated by 14 days. There will be a 6-week follow-up period.

Subjects will randomly be assigned to double-blind treatment with one of 4 dose levels of MEDI7352 or placebo

Clinical Study Identifier: NCT03755934

Find a site near you

Start Over

Research Site

Stockton-on-Tees, United Kingdom
  Connect »